|
1
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS Statistical Report: Primary brain and central nervous system
tumors diagnosed in the United States in 2008–2012. Neuro-oncology.
17 (Suppl 4):iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fernandez A, Karavitaki N and Wass JA:
Prevalence of pituitary adenomas: A community-based,
cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol
(Oxf). 72:377–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009.
Neuro Oncol. 14 (Suppl 5):v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Asa SL and Ezzat S: The cytogenesis and
pathogenesis of pituitary adenomas. Endocr Rev. 19:798–827. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Daly AF, Rixhon M, Adam C, Dempegioti A,
Tichomirowa MA and Beckers A: High prevalence of pituitary
adenomas: A cross-sectional study in the province of Liege,
Belgium. J Clin Endocrinol Metab. 91:4769–4775. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dekkers OM, Pereira AM and Romijn JA:
Treatment and follow-up of clinically nonfunctioning pituitary
macroadenomas. J Clin Endocrinol Metabol. 93:3717–3726. 2008.
View Article : Google Scholar
|
|
7
|
Ntali G and Wass JA: Epidemiology,
clinical presentation and diagnosis of non-functioning pituitary
adenomas. Pituitary. 21:111–118. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Agustsson TT, Baldvinsdottir T, Jonasson
JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV,
Carroll PV, Korbonits M and Benediktsson R: The epidemiology of
pituitary adenomas in Iceland, 1955–2012: A nationwide
population-based study. Eur J Endocrinol. 173:655–664. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen L, White WL, Spetzler RF and Xu B: A
prospective study of nonfunctioning pituitary adenomas:
Presentation, management, and clinical outcome. J Neurooncol.
102:129–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shomali ME and Katznelson L: Medical
therapy of gonadotropin-producing and nonfunctioning pituitary
adenomas. Pituitary. 5:89–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meij BP, Lopes MB, Ellegala DB, Alden TD
and Laws ER Jr: The long-term significance of microscopic dural
invasion in 354 patients with pituitary adenomas treated with
transsphenoidal surgery. J Neurosurg. 96:195–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brochier S, Galland F, Kujas M, Parker F,
Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D and
Chanson P: Factors predicting relapse of nonfunctioning pituitary
macroadenomas after neurosurgery: A study of 142 patients. Eur J
Endocrinol. 163:193–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferrante E, Ferraroni M, Castrignanò T,
Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli
P, Faustini-Fustini M, et al: Non-functioning pituitary adenoma
database: A useful resource to improve the clinical management of
pituitary tumors. Eur J Endocrinol. 155:823–829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greenman Y, Ouaknine G, Veshchev I, Reider
G II, Segev Y and Stern N: Postoperative surveillance of clinically
nonfunctioning pituitary macroadenomas: Markers of tumour
quiescence and regrowth. Clin Endocrinol (Oxf). 58:763–769. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dekkers OM, Pereira AM, Roelfsema F,
Voormolen JH, Neelis KJ, Schroijen MA, Smit JW and Romijn JA:
Observation alone after transsphenoidal surgery for nonfunctioning
pituitary macroadenoma. J Clin Endocrinol Metab. 91:1796–1801.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brada M and Jankowska P: Radiotherapy for
pituitary adenomas. Endocrinol Metab Clin North Am. 37263–275.
(xi)2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pollock BE, Cochran J, Natt N, Brown PD,
Erickson D, Link MJ, Garces YI, Foote RL, Stafford SL and Schomberg
PJ: Gamma knife radiosurgery for patients with nonfunctioning
pituitary adenomas: Results from a 15-year experience. Int J Radiat
Oncol Biol Phys. 70:1325–1329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mehta GU and Lonser RR: Management of
hormone-secreting pituitary adenomas. Neuro Oncol. 19:762–773.
2017.PubMed/NCBI
|
|
19
|
Uraki S, Ariyasu H, Doi A, Kawai S,
Takeshima K, Morita S, Fukai J, Fujita K, Furuta H, Nishi M, et al:
Reduced expression of mismatch repair genes MSH6/MSH2 directly
promotes pituitary tumor growth via the ATR-Chk1 pathway. J Clin
Endocrinol Metab. 103:1171–1179. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Long R, Liu Z, Li J and Yu H: COL6A6
interacted with P4HA3 to suppress the growth and metastasis of
pituitary adenoma via blocking PI3K-Akt pathway. Aging (Albany NY).
11:8845–8859. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu YH and Feng YG: Down-regulation of
TGF-β RII expression is correlated with tumor growth and invasion
in non-functioning pituitary adenomas. J Clin Neurosci. 47:264–268.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu H, Yao X, Wu L, Li C, Bai J, Gao H, Ji
H and Zhang Y: Association of TGF-β1 and WIF1 expression with 36
paired primary/recurrent nonfunctioning pituitary adenomas: A
high-throughput tissue microarrays immunohistochemical study. World
Neurosurg. 119:e23–e31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song W, Qian L, Jing G, Jie F, Xiaosong S,
Chunhui L, Yangfang L, Guilin L, Gao H and Yazhuo Z: Aberrant
expression of the sFRP and WIF1 genes in invasive non-functioning
pituitary adenomas. Mol Cell Endocrinol. 474:168–175. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859:169–176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu D, Su C, Jiang M, Shen Y, Shi A, Zhao
F, Chen R, Shen Z, Bao J and Tang W: Fenofibrate inhibited
pancreatic cancer cells proliferation via activation of p53
mediated by upregulation of LncRNA MEG3. Biochem Biophys Res
Commun. 471:290–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang W, Shi S, Jiang J, Li X, Lu H and
Ren F: lncRNA MEG3 inhibits cell epithelial-mesenchymal transition
by sponging miR-421 targeting E-cadherin in breast cancer. Biomed
Pharmacother. 91:312–319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu T, Wu K and Zhang L, Zheng S, Wang X,
Zuo H, Wu X, Tao G, Jiang B and Zhang L: Long non-coding RNA
LINC00858 exerts a tumor-promoting role in colon cancer via
HNF4alpha and WNK2 regulation. Cell Oncol (Dordr). 43:297–310.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu H, Zhao G, Zhang Y, Jiang H, Wang W,
Zhao D, Yu H and Qi L: Long non-coding RNA PAXIP1-AS1 facilitates
cell invasion and angiogenesis of glioma by recruiting
transcription factor ETS1 to upregulate KIF14 expression. J Exp
Clin Cancer Res. 38:4862019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou S, Wang L, Yang Q, Liu H, Meng Q,
Jiang L, Wang S and Jiang W: Systematical analysis of lncRNA-mRNA
competing endogenous RNA network in breast cancer subtypes. Breast
Cancer Res Treat. 169:267–275. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo Q, Cheng Y, Liang T, He Y, Ren C, Sun
L and Zhang G: Comprehensive analysis of lncRNA-mRNA co-expression
patterns identifies immune-associated lncRNA biomarkers in ovarian
cancer malignant progression. Sci Rep. 5:176832015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang ZL, Zhao LJ, Chai L, Zhou SH, Wang
F, Wei Y, Xu YP and Zhao P: Seven LncRNA-mRNA based risk score
predicts the survival of head and neck squamous cell carcinoma. Sci
Rep. 7:3092017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lopes MBS: The 2017 World Health
Organization classification of tumors of the pituitary gland: A
summary. Acta Neuropathol. 134:521–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tusher VG, Tibshirani R and Chu G:
Significance analysis of microarrays applied to the ionizing
radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Goel R, Muthusamy B, Pandey A and Prasad
TS: Human protein reference database and human proteinpedia as
discovery resources for molecular biotechnology. Mol Biotechnol.
48:87–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chatr-Aryamontri A, Oughtred R, Boucher L,
Rust J, Chang C, Kolas NK, O'Donnell L, Oster S, Theesfeld C,
Sellam A, et al: The BioGRID interaction database: 2017 update.
Nucleic Acids Res. 45:D369–D379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Du ZP, Wu BL, Wu X, Lin XH, Qiu XY, Zhan
XF, Wang SH, Shen JH, Zheng CP, Wu ZY, et al: A systematic analysis
of human lipocalin family and its expression in esophageal
carcinoma. Sci Rep. 5:120102015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bindea G, Mlecnik B, Hackl H, Charoentong
P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and
Galon J: ClueGO: A Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks.
Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin X, Jiang T, Bai J, Li J, Wang T, Xiao
J, Tian Y, Jin X, Shao T, Xu J, et al: Characterization of
transcriptome transition associates long noncoding RNAs with glioma
progression. Mol Ther Nucleic Acids. 13:620–632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yin X, Wang P, Yang T, Li G, Teng X, Huang
W and Yu H: Identification of key modules and genes associated with
breast cancer prognosis using WGCNA and ceRNA network analysis.
Aging (Albany NY). 12:2020.
|
|
44
|
Kang Z, Guo L, Zhu Z and Qu R:
Identification of prognostic factors for intrahepatic
cholangiocarcinoma using long non-coding RNAs-associated ceRNA
network. Cancer Cell Int. 20:3152020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tjörnstrand A, Gunnarsson K, Evert M,
Holmberg E, Ragnarsson O, Rosén T and Filipsson Nyström H: The
incidence rate of pituitary adenomas in western Sweden for the
period 2001–2011. Eur J Endocrinol. 171:519–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Olsson DS, Nilsson AG, Bryngelsson IL,
Trimpou P, Johannsson G and Andersson E: Excess mortality in women
and young adults with nonfunctioning pituitary adenoma: A Swedish
Nationwide Study. J Clin Endocrinol Metabol. 100:2651–2658. 2015.
View Article : Google Scholar
|
|
47
|
Freda PU, Beckers AM, Katznelson L,
Molitch ME, Montori VM, Post KD and Vance ML; Endocrine Society, :
Pituitary incidentaloma: An endocrine society clinical practice
guideline. J Clin Endocrinol Metab. 96:894–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tampourlou M, Ntali G, Ahmed S, Arlt W,
Ayuk J, Byrne JV, Chavda S, Cudlip S, Gittoes N, Grossman A, et al:
Outcome of nonfunctioning pituitary adenomas that regrow after
primary treatment: A study from two large UK centers. J Clin
Endocrinol Metab. 102:1889–1897. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hasanov R, Aydogan BI, Kiremitci S, Erden
E and Gullu S: The Prognostic roles of the Ki-67 proliferation
index, P53 expression, mitotic index, and radiological tumor
invasion in pituitary adenomas. Endocr Pathol. 30:49–55. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng S, Wu J, Li C, Li Y, Liu C, Li G, Li
W, Hu S, Ying X and Zhang Y: Predicting the regrowth of clinically
non-functioning pituitary adenoma with a statistical model. J
Transl Med. 17:1642019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Guo J, Wang Z, Miao Y, Shen Y, Li M, Gong
L, Wang H, He Y, Gao H, Liu Q, et al: A two-circRNA signature
predicts tumour recurrence in clinical non-functioning pituitary
adenoma. Oncol Rep. 41:113–124. 2019.PubMed/NCBI
|
|
52
|
Chen X, Dai M, Zhu H, Li J, Huang Z, Liu
X, Huang Y, Chen J and Dai S: Evaluation on the diagnostic and
prognostic values of long non-coding RNA BLACAT1 in common types of
human cancer. Mol Cancer. 16:1602017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu ZR, Yan L, Liu YT, Cao L, Guo YH, Zhang
Y, Yao H, Cai L, Shang HB, Rui WW, et al: Inhibition of mTORC1 by
lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary
tumours. Nat Commun. 9:46242018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang Y, Liu YT, Tang H, Xie WQ, Yao H, Gu
WT, Zheng YZ, Shang HB, Wang Y, Wei YX, et al: Exosome-transmitted
lncRNA H19 inhibits the growth of pituitary adenoma. J Clin
Endocrinol Metab. 104:6345–6356. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xing W, Qi Z, Huang C, Zhang N, Zhang W,
Li Y, Qiu M, Fang Q and Hui G: Genome-wide identification of
lncRNAs and mRNAs differentially expressed in non-functioning
pituitary adenoma and construction of an lncRNA-mRNA co-expression
network. Biol Open. 8:bio0371272019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen L, Liu D, Yi X, Qi L, Tian X, Sun B,
Dong Q, Han Z, Li Q, Song T, et al: The novel miR-1269b-regulated
protein SVEP1 induces hepatocellular carcinoma proliferation and
metastasis likely through the PI3K/Akt pathway. Cell Death Dis.
11:3202020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ichikawa T, Okugawa Y, Toiyama Y, Tanaka
K, Yin C, Kitajima T, Kondo S, Shimura T, Ohi M, Araki T and
Kusunoki M: Clinical significance and biological role of L1 cell
adhesion molecule in gastric cancer. Br J Cancer. 121:1058–1068.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Marques P, Barry S, Carlsen E, Collier D,
Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, et
al: Chemokines modulate the tumour microenvironment in pituitary
neuroendocrine tumours. Acta Neuropathol Commun. 7:1722019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ma S, Lu CC, Yang LY, Wang JJ, Wang BS,
Cai HQ, Hao JJ, Xu X, Cai Y, Zhang Y and Wang MR: ANXA2 promotes
esophageal cancer progression by activating MYC-HIF1A-VEGF axis. J
Exp Clin Cancer Res. 37:1832018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tan SH, Young D, Chen Y, Kuo HC,
Srinivasan A, Dobi A, Petrovics G, Cullen J, Mcleod DG, Rosner IL,
et al: Prognostic features of Annexin A2 expression in prostate
cancer. Pathology. 2020.(Online ahead of print).
|
|
61
|
Zhuang C, Wang P, Sun T, Zheng L and Ming
L: Expression levels and prognostic values of annexins in liver
cancer. Oncol Lett. 18:6657–6669. 2019.PubMed/NCBI
|
|
62
|
Liu X, Ma D, Jing X, Wang B, Yang W and
Qiu W: Overexpression of ANXA2 predicts adverse outcomes of
patients with malignant tumors: A systematic review and
meta-analysis. Med Oncol. 32:3922015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Utama B, Kennedy D, Ru K and Mattick JS:
Isolation and characterization of a new nucleolar protein, Nrap,
that is conserved from yeast to humans. Genes Cells. 7:115–132.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dong D, Song M, Wu X and Wang W: NOL6, a
new founding oncogene in human prostate cancer and targeted by
miR-590-3p. Cytotechnology. 72:469–478. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang W, Snyder N, Worth AJ, Blair IA and
Witze ES: Regulation of lipid synthesis by the RNA helicase Mov10
controls Wnt5a production. Oncogenesis. 4:e1542015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Nakano M, Kakiuchi Y, Shimada Y, Ohyama M,
Ogiwara Y, Sasaki-Higashiyama N, Yano N, Ikeda F, Yamada E,
Iwamatsu A, et al: MOV10 as a novel telomerase-associated protein.
Biochem Biophys Res Commun. 388:328–332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tang Y, Xie C, Zhang Y, Qin Y and Zhang W:
Overexpression of mRNA-decapping enzyme 1a predicts
disease-specific survival in malignant melanoma. Melanoma Res.
28:30–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wu C, Liu W, Ruan T, Zhu X, Tao K and
Zhang W: Overexpression of mRNA-decapping enzyme 1a affects
survival rate in colorectal carcinoma. Oncol Lett. 16:1095–1100.
2018.PubMed/NCBI
|
|
69
|
Shi C, Liu T, Chi J, Luo H, Wu Z, Xiong B,
Liu S and Zeng Y: LINC00339 promotes gastric cancer progression by
elevating DCP1A expression via inhibiting miR-377-3p. J Cell
Physiol. 234:23667–23674. 2019. View Article : Google Scholar : PubMed/NCBI
|
